Therapeutics for Neurodegenerative Diseases
Company Founded Year
Company Number of Employees
Biotechnology & Biopharmaceutical
Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases.
The companyâ€™s lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction. The drug has demonstrated in vivo efficacy in animal models of Huntingtonâ€™s disease and Parkinsonâ€™s disease, and it has shown beneficial activity in patient-derived cells of Huntingtonâ€™s disease, sporadic and genetic Parkinsonâ€™s disease, and sporadic and genetic Alzheimerâ€™s disease.